GlassScriptPhysician profile
Anthony P Piazza
NPI 1164855003
$3,991.07
in general payments reported to CMS, 2019-2025
19 companies · $2,235 in 2025
The $2,235 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.71 · 2022: $355 · 2023: $550 · 2024: $754 · 2025: $2,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,538.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,484.76 | 2025 | Rapiblyk |
| Pfizer INC. | $411.62 | 2023-2025 | |
| Csl Behring | $290.68 | 2022-2025 | Kcentra |
| Abbvie INC. | $256.07 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $240.20 | 2023-2025 | Rebyota |
| Alexion Pharmaceuticals, INC. | $171.91 | 2022-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.64 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.24 | 2022-2025 | Xifaxan |
| Shionogi INC | $138.94 | 2022-2025 | Fetroja |
| Merck Sharp & Dohme LLC | $135.85 | 2022-2024 | Dificid, Zerbaxa, Recarbrio |
| Astrazeneca Pharmaceuticals LP | $132.40 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $131.84 | 2022-2025 | Camzyos, Eliquis |
| Aimmune Therapeutics, INC. | $99.92 | 2025 | Vowst |
| Janssen Pharmaceuticals, INC | $87.13 | 2022-2023 | Xarelto |
| Vifor Pharma, INC. | $34.57 | 2022-2023 | Veltassa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $24.08 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $21.45 | 2024 | |
| Melinta Therapeutics, LLC | $17.53 | 2024 | Kimyrsa, Rezzayo |
| Paratek Pharmaceuticals, INC. | $15.24 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Piazza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.